Also Read
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
The mRNA vaccines do not use the conventional model to produce immune response. Instead, it carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus.
India's first indigenous COVID-19 mRNA vaccine candidate has received approval from the Drug Controller General of India to initiate Phase I/II human clinical trial, the Ministry of Earth Sciences said on Friday. The novel mRNA vaccine candidate, HGCO19 has been developed by Gennova, a Pune-based company and supported with seed grant under the Ind-CEPI mission of Department of Biotechnology of Science and Technology Ministry.
The mRNA vaccines do not use the conventional model to produce immune response. Instead, it carries the molecular instructions to make the protein in the body through a synthetic RNA of the virus. The host body uses this to produce the viral protein that is recognised and thereby making the body mount an immune response against the disease. According to many experts, mRNA-based vaccines are scientifically the ideal choice to address a pandemic because of their rapid developmental timeline. These are considered safe because they are non-infectious and non-integrating in nature. They can also not be degraded by standard cellular mechanisms.
mRNA-based vaccines are expected to be highly efficacious because of their inherent capability of being translatable into the protein structure inside the cell cytoplasm. Additionally, these are fully synthetic and do not require a host for growth, e.g., eggs or bacteria. Therefore, they can be quickly manufactured in an inexpensive manner under cGMP conditions to ensure their "availability" and "accessibility" for mass vaccination on a sustainable basis.
Also Read
Also Read
Also Read
Gennova, in collaboration with HDT Biotech Corporation, Seattle, USA, has worked together to develop this vaccine candidate, HGCO19. It has already demonstrated safety, immunogenicity, neutralization antibody activity in animals. The neutralising antibody response of the vaccine in mice and non-human primates was comparable with the sera from the convalescent patients of COVID-19.
Gennova's vaccine candidate uses the most prominent mutant of spike protein (D614G) and also uses the self-amplifying mRNA platform, which gives the advantage of a low dosing regimen compared with the non-replicating mRNA or traditional vaccines. HGCO19 uses the adsorption chemistry so that the mRNA is attached on the surface of the nano-lipid carrier to enhance the release kinetics of the mRNA within the cells compared to the encapsulation chemistry.
This vaccine is stable at 2-8 degrees Celsius for two months. Gennova has completed all preliminary work and should be initiating the Phase I/II Human clinical trial soon since the approval from the DCGI office has been received. The Department of Biotechnology is implementing the IndCEPImission 'India Centric Epidemic Preparedness through Rapid Vaccine Development: Supporting Indian Vaccine Development' which is aligned with the Global Initiative of CEPIand aims to strengthen the development of vaccines and associated technologies for the diseases of epidemic potential in India. The Ind-CEPI mission of DBT is implemented by its PSU, Biotechnology Industry Research Assistance Council ( BIRAC). "Establishment of a such indigenous technology platform will not only empower India to handle the COVID-19 pandemic but also ensure the preparedness for future outbreaks," said Dr Renu Swarup, Secretary, Department of Biotechnology and Chairperson BIRAC.
(With inputs from IANS)